Thank you for being interested in Investing into QURES GROUP LTD
We are a new start-up company that has technology ready to present to various commercial markets around the world, with answers to some of the biggest problems the planet faces.
QURES GROUP LTD will gather all the IP and knowhow relating to HYPOTHIOCYANITE and to transfer responsibility and control of this ASSET to Qures Academy. Because the technology and availability of HYPOTHIOCYANITE is NEW, it is our intention to establish THE QURES ACADEMY to ensure full and correct knowledge and understanding is available to our Licensees and their clients.
The QURES Academy will have the responsibility to protect and enhance the competence of the IP, Our Teachers and Trainers will travel as necessary and residential courses will also be available. The Academy, with the close involvement with our Licensees, will allow QURES to monitor, protect and maintain our leadership of HYPOTHIOCYANITE IP.
Quickly we will start clinical work to verify the safety of the molecule and then human clinical trials against one or more conditions. Whilst numerous academic papers have shown positive results against a wide range of pathogens, including resistant strains, already, we anticipate that regulators will be looking for evidence created using more modern techniques and standards.
Some of this work is already being negotiated and the first of several animal and human clinical trials will happen very soon, after the Safety status is confirmed.
The acknowledgement of the safety to humans of the technology will make our introduction to all other application and licensees so much easier.
Income
We will earn income from selling licences (big and small) around the world followed by royalties, also big and small, from the successes of the Licensees. Licensees to come from interested, competent and capable parties involved both geographically, commercially and experienced in the application areas of the technology. We will always have an involvement in any activities/IP based on or utilising our technology to ensure it is protected and enhanced and to enable us to widen our licencing of the technology and enhancing value for and from our licensees.
The extent of direct or indirect marketing and sales by QURES will be reviewed by independent consultants to determine, assess and compare the relative values of each possible method so as to assist us to identify how we promote the technology to the many different applications and opportunities.
HEALTH will be our initial target market and we intend to retain that licence in our wholly owned subsidiary, UBIQ MEDICINES LTD, as we anticipate that industrial sector to be the largest. As we develop UBIQ MEDICINES, we can seek/consider investment into UBIQ from interested parties.
We see enormous benefits for users of the Qures Technology.
1.Overcome Antibiotic Resistance (ABR and AMR).
2.Reduce time in hospital for recovery from infections.
3.Faster delivery of an effective treatment without having to wait for diagnosis
4.Shorten the period away from work for employees on the 3-4 occasions each year that URTI infections leave them unable to work.
5.Eventually have the products regulated and allowed for OTC availability.
These attributes and cost savings will be of enormous interest to Hospitals, Insurance companies and Governments, plus employers will be able to reduce lost working days by their employees. Benefits not available when using existing treatment methods.
Other industries will find similar benefits of involvement with Qures. These benefits will be explained and verified for presentations to potential licensees.
Marketing opportunities
- The human healthcare market for treatments to fight pathogenic disease is valued in excess of US$50 Bn,
- add to that Animal treatments at US$4.5Bn,
- Air treatments at USD5.7 Bn and
- Food/Agriculture value said to be US$9.0Bn
- plus various miscellaneous opportunities in excess of US$1.Bn.
- The Markets are all worldwide.
Value of target markets for QURES and its Licensees is estimated at US$70bn today and we have every reason to believe that the introduction of QURES’s Technology could increase the combined market values close to US$100Bn within the next 10 years.
The sales values of our technology will probably be variable within and compared to other licensees. Recognition of affordability for the different countries and their economic stability and strengths will influence our pricing policy individually for Licensees.
Pathogen treatments exist already in the below industries. They are all reliant upon inadequate antimicrobial solutions. The markets are open to, and all are desperate for, better products.
Investors
If you want to become financially involved with this exciting venture into the future of human and planet health worldwide, please, complete and submit the INTEREST FORM below. The more information you can provide, that explains who you are and why an investment in QURES is of interest, the better able we are to respond specifically to you. Upon receipt of your INTEREST FORM we will send a CONFIDENTIALITY AGREEMENT (CDA) Following receipt of the signed CDA, we will send you an up to date summary of the current status of QURES.
The signed CDA that ensures the use of any confidential details, we share with you, is exclusively to evaluate your investment in QURES GROUP LTD.
You can expect a prompt reply, following our acknowledgement of your interest. Once you become an Investor, you will be granted full access to our Investor site so you can keep abreast of what we are planning, doing and achieving.